Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Shares Issued (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Shares Issued for 6 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 18.2% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 56.98% year-over-year, with the annual reading at $10.2 million for FY2025, 56.98% up from the prior year.
  • Shares Issued hit $2.6 million in Q4 2025 for Harmony Biosciences Holdings, up from $754000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $28.2 million in Q4 2021 to a low of $12000.0 in Q1 2021.
  • Historically, Shares Issued has averaged $3.0 million across 5 years, with a median of $1.6 million in 2022.
  • Biggest five-year swings in Shares Issued: soared 176187.5% in 2021 and later plummeted 97.03% in 2024.
  • Year by year, Shares Issued stood at $28.2 million in 2021, then tumbled by 87.36% to $3.6 million in 2022, then plummeted by 93.63% to $227000.0 in 2023, then soared by 1325.99% to $3.2 million in 2024, then dropped by 18.2% to $2.6 million in 2025.
  • Business Quant data shows Shares Issued for HRMY at $2.6 million in Q4 2025, $754000.0 in Q3 2025, and $2.1 million in Q2 2025.